OncoMethylome
Sciences and GlaxoSmithKline Biologicals will collaborate to develop
DNA methylation biomarkers for use in the personalization of
cancer treatment with certain immunotherapeutics in development by
GSK Biologicals.
"We look forward to using our high-throughput platform to efficiently test our portfolio of methylation biomarkers on clinical samples provided by GSK Biologicals," commented Jim DiGuiseppi, CTO of OncoMethylome.